The treatment of restless legs syndrome and periodic limb movement disorder in adults - An update for 2012: Practice parameters with an evidence-based systematic review and meta-analyses

Sleep

Volumn 35, Issue 8, 2012, Pages 1039-1062

  Aurora, R Nisha ^a   Kristo, David A ^b   Bista, Sabin R ^c   Rowley, James A ^d   Zak, Rochelle S ^e   Casey, Kenneth R ^f   Lamm, Carin I ^g   Tracy, Sharon L ^h   Rosenberg, Richard S ^h  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h American Academy of Sleep Medicine   (United States)

Author keywords

Periodic limb movement disorder; PLMD; Restless legs syndrome; RLS; Sleep related movement disorders

Indexed keywords

AMANTADINE; CABERGOLINE; CARBAMAZEPINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLONIDINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; GABAPENTIN; GABAPENTIN ENACARBIL; IRON DEXTRAN; LEVODOPA; LISURIDE; OPIATE; PERGOLIDE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; TALIPEXOLE; TRAMADOL; UNINDEXED DRUG;

ACTIMETRY; ADD ON THERAPY; ADULT; ANXIETY SCALE; APPLICATION SITE REACTION; AUGMENTATION SEVERITY RATING SCALE; BACKACHE; BEHAVIOR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COMPULSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIZZINESS; DOPAMINE DYSREGULATION SYNDROME; DRUG EFFICACY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; EVIDENCE BASED PRACTICE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERPHAGIA; HYPERSEXUALITY; HYPOTENSION; IMPULSE CONTROL DISORDER; IRLS RATING SCALE; LIBIDO DISORDER; LIVER DISEASE; LOW DRUG DOSE; MEDICAL OUTCOMES STUDY SLEEP SCALE; MEDICAL PRACTICE; META ANALYSIS; NAUSEA; PATHOLOGICAL GAMBLING; PATIENT GLOBAL IMPRESSION; PERIODIC LIMB MOVEMENT DISORDER; PITTSBURGH SLEEP QUALITY INDEX; POLYSOMNOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLACTINOMA; QUALITY OF LIFE FOR RLS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; RHINOPHARYNGITIS; SEDATION; SELF RATING ZUNG DEPRESSION SCALE; SHORT FORM 36; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP QUESTIONNAIRE FORM A; SOMNOLENCE; STANDARD; STEVENS JOHNSON SYNDROME; SUBJECTIVE SLEEP AND AWAKENING QUALITY SCALE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SYSTEMATIC REVIEW; UNSTEADINESS; VALVULAR HEART DISEASE; VEIN INSUFFICIENCY; VISUAL ANALOG SCALE; VISUAL DISORDER; VOMITING; XEROSTOMIA;

PERIODIC LIMB MOVEMENT DISORDER; PLMD; RESTLESS LEGS SYNDROME; RLS; SLEEP-RELATED MOVEMENT DISORDERS;

ACADEMIES AND INSTITUTES; BENZOTHIAZOLES; CARBAMATES; DOPAMINE AGENTS; ERGOLINES; EVIDENCE-BASED MEDICINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INDOLES; LEVODOPA; NOCTURNAL MYOCLONUS SYNDROME; PERGOLIDE; PERIPHERAL NERVOUS SYSTEM DISEASES; RESTLESS LEGS SYNDROME; SLEEP MEDICINE SPECIALTY; UNITED STATES; VENOUS INSUFFICIENCY;

EID: 84864762471     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.1988     Document Type: Review

References (155)

1. Balshem H, Helfand M, Schunemann H, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
2. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M. The treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999;22:970-99. (Pubitemid 29526518)
3. Hening W, Allen R, Earley C, Picchietti D, Silber M. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-83. (Pubitemid 44138822)
4. Littner M, Kushida C, McDowell Anderson W, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:557-9. (Pubitemid 44138821)
5. Chesson A, Wise M, Davila D, et al. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. Sleep 1999;22:961-8. (Pubitemid 29526517)
6. American Academy of Sleep Medicine. ICSD-2: International classification of sleep disorders, 2nd Edition: Diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine, 2005.
7. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19. (Pubitemid 36527231)
8. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-32.
9. Clinical global impression (CGI). In: Guy M, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 1976.
10. Higgins J, Green S, (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. In: The Cochrane Collaboration.
11. Bax L, Yu L, Ikeda N, Tsuruta H, Moons K. Development and validation of MIX: Comprehensive free software for meta-analysis of causal research data. BMC Medical Res Methodol 2006 Oct 13;6:50.
12. Bax L, Yu L, Ikeda N, Tsuruta H, Moons K. MIX: Comprehensive free software for meta-analysis of causal research data. Version 1.7. http://mix-for-meta-analysis.info. 2008.
13. Guyatt G, Oxman A, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
14. Zaza S, Wright-DeAguaero LK, Briss P, et al. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Am J Prev Med 2000;18:44-74. (Pubitemid 30114234)
15. Brozek J, Oxman A, Schunemann H. GRADEPro [Computer program]. In: Versions 3.0.1 and 3.2.2 for Windows, 2008.
16. Atkins D, Best D, Briss P, et al. Grading and quality of evidence and strength of recommendations. BMJ 2004;328:1490-94.
17. Schunemann H, Jaeschke R, Cook D, et al. An official ATS statement: Grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006;174:605-14. (Pubitemid 44330555)
18. Aurora R, Morgentahaler T. On the Goodness of Recommendations: The Changing Face of Practice Parameters. Sleep 2010;33:1273-76.
19. Fulda S, Wetter T. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008;131:902-17. (Pubitemid 351499412)
20. Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010;33:81-7.
21. Ondo W, Lai D. Predictors of impulsivity and reward-seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008;14:28-32.
22. Driver-Dunckley E, Noble BN, Hentz J, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007;30:249-55. (Pubitemid 47511504)
23. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-70.
24. Leu-Semenescu S, Karroum E, Brion A, Konofal E, Arnulf I. Dopamine dysregulation syndrome in a patient with restless legs syndrome. Sleep Med 2009;10:494-6.
25. Salas RE, Allen RP, Earley CJ, Gamaldo CE. Drug hoarding: a case of atypical dopamine dysregulation syndrome in a RLS patient. Mov Disord 2009;24:627-8.
26. Tippmann-Peikert M, Park JG, Boeve BF, Shepard JW, Silber MH. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007;68:301-3. (Pubitemid 46148346)
27. Quickfall J, Suchowersky O. Pathological gambling associated with dopaminergic agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007;13:535-6. (Pubitemid 350110554)
28. Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007;22:590-1. (Pubitemid 46608168)
29. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
30. Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874-81.
31. Winkelman J, Sethi K, Kushida C, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9. (Pubitemid 44454599)
32. Oertel W, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (Effect-RLS Study). Mov Disord 2007;22:213-9. (Pubitemid 46374764)
33. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study - the PRELUDE study. Sleep Med 2006;7:407-17. (Pubitemid 44130411)
34. Inoue Y, Hirata K, Kuroda K, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med 2010;11:11-6.
35. Jama L, Hirvonen K, Partinen M, et al. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance. Sleep Med 2009;10:630-6.
36. Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12:34-40.
37. Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T. Efficacy, safety and dose-response of pramipexole in Japanese patients with primary restless legs syndrome: Randomized trial. Neuropsychobiology 2011;63:35-42.
38. Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T. Longterm open-label study of pramipexole in patients with primary restless legs syndrome. J Neurol Sci 2010;294:62-6.
39. Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Med 2008;9:537-41.
40. Hornyak M, Sohr M, Busse M. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials. Sleep Med 2011;12:186-9.
41. Saletu M, Anderer P, Saletu-Zyhlarz G, Hauer C, Saletu B. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci 2002;252:185-94. (Pubitemid 36056675)
42. Stiasny-Kolster K, Oertel W. Low-dose pramipexole in the management of restless legs syndrome. Neuropsychobiology 2004;50:65-70. (Pubitemid 38721172)
43. Silber M, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: An extended study. Sleep 2003;26:819-21. (Pubitemid 39610626)
44. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-10. (Pubitemid 44613292)
45. Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study. Sleep Med 2006;7:407-17. (Pubitemid 44130411)
46. Winkelman J, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 2004;5:9-14. (Pubitemid 38145706)
47. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;12:440-4.
48. Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: A placebo-controlled crossover trial. Neurology 2004;62:1405-7. (Pubitemid 38526058)
49. Bogan R, Fry J, Schmidt M, Carson S, Ritchie S, for the TREAT RLS US (Therapy with Ropinirole Efficacy and Tolerability in RLS US) Study Group. Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27. (Pubitemid 43054313)
50. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12-week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7. (Pubitemid 38091275)
51. Walters A, Ondo W, Dreykluft T, Grunstein R, Lee D, Sethi K. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-23. (Pubitemid 40104048)
52. Bliwise D, Freeman A, Ingram C, Rye D, Chakravorty S, Watts R. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 2005;6:141-7. (Pubitemid 40247176)
53. Allen R, Becker P, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-14. (Pubitemid 39095723)
54. Kushida C, Geyer J, Tolson J, Asgharian A. Patient- and physician-rated measures demonstrate the effectiveness of Ropinirole in the treatment of restless legs syndrome. Clin Neuropharmacol 2008;31:281-6.
55. Montplaisir J, Karrasch J, Haan J, Volc D. Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial. Mov Disord 2006;21:1627-35. (Pubitemid 44742190)
56. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-52. (Pubitemid 47553544)
57. Giorgi L, Ritchie SY, Kirsch JM. Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points - data from the ropinirole clinical trial programme. Curr Med Res Opin 2006;22:1867-77. (Pubitemid 44663389)
58. Saletu M, Anderer P, Hogl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm 2003;110:611-26. (Pubitemid 36683515)
59. Trenkwalder C, Seidel V, Kazenwadel J, et al. One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? Mov Disord 2003;18:1184-9. (Pubitemid 37336945)
60. Polo O, Yla-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmen J. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome. Clin Neuropharmacol 2007;30:335-44. (Pubitemid 350307312)
61. Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010 Feb;257:230-7.
62. Trenkwalder C, Hundemer H, Lledo A, et al. Efficacy of pergolide in treatment of restless legs syndrome. Neurology 2004;62:1391-7. (Pubitemid 38526054)
63. Oertel W, Benes H, Bodenschatz R, et al. Efficacy of cabergoline in restless legs syndrome: A placebo-controlled study with polysomnography (CATOR). Neurology 2006;67:1040-6. (Pubitemid 44454600)
64. Stiasny-Kolster K, Benes H, Peglau I, et al. Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 2004;63:2272-9. (Pubitemid 40024336)
65. Zucconi M, Oldani A, Castronovo C, Ferini-Strambi L. Cabergoline is an effective single-drug treatment for restless legs syndrome: Clinical and actigraphic evaluation. Sleep 2003;26:815-8. (Pubitemid 39610625)
66. Benes H, Heinrich C, Ueberall M, Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: Results from an open-label 6-month clinical trial. Sleep 2004;27:674-82. (Pubitemid 38823364)
67. Trenkwalder C, Benes H, Grote L, et al. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov Disord 2007;22:696-703. (Pubitemid 46800141)
68. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's Disease. N Engl J Med 2007;356:39-46. (Pubitemid 46041752)
69. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot-derived dopamine agonists. Mov Disord 2009;24:129-33.
70. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009;70:104-8.
71. Natchtigall LB, Valassi E, Lo J, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 2010;72:53-8.
72. Peralta CM, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006;21:1109-13. (Pubitemid 44348515)
73. Simonis G, Fuhrmann JT, Strasser RH. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists. Mov Disord 2007;22:1936-42. (Pubitemid 350134208)
74. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 2010;73:369-74.
75. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006;67:1225-9. (Pubitemid 44563832)
76. Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23. (Pubitemid 24054963)
77. Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 1993;16:327-32. (Pubitemid 23176289)
78. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry 1999;60:241-4. (Pubitemid 29193922)
79. Walters A, Winkelman J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;16:1105-9. (Pubitemid 36041223)
80. Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord 2005;20:345-8. (Pubitemid 40613296)
81. Vetrugno R, La Morgia C, D'Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 2007;22:424-7. (Pubitemid 46569705)
82. Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46.
83. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-68.
84. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311-20.
85. Lee DO, Ziman MD, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011;7:282-92.
86. Kushida C, Walters A, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-68.
87. Winkelman J, Bogan R, Schmidt MH, Hudson JD, Derossett SE, Hill-Zabala CE. Randomized polysomnography sudy of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011;Epub ahead of print.
88. Ellenbogen AL, Thein SG, Winslow D, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011;34:8-16.
89. Bogan RK, Bornemann MA, Kushida CA, Tran PV, Barrett RW. Longterm maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc 2010;85:512-21.
90. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003;48:82-6. (Pubitemid 37176872)
91. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over study. Neurology 2002;59:1573-9. (Pubitemid 35387065)
92. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-9.
93. Garcia-Borreguero D, Larrosa O, Williams AM, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology 2010;74:1897-904.
94. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J 1984;288:444-6. (Pubitemid 14121123)
95. Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs: A controlled pilot study. Eur J Clin Pharmacol 1983;25:323-4. (Pubitemid 13005576)
96. Zucconi M, Coccagna G, Petronelli R, Gerardi R, Mondini S, Cirignotta F. Nocturnal myoclonus in restless legs syndrome: effect of carbamazepine treatment. Funct Neurol 1989;4:263-71. (Pubitemid 19216422)
97. Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 1996;19:52-8. (Pubitemid 26053150)
98. Ausserwinkler M, Schmidt P. [Successful clonidine treatment of restless legs syndrome in chronic kidney insufficiency]. Schweiz Med Wochenschr 1989;119:184-6.
99. Davis B, Rajput A, Rajput M, Aul E, Eichhorn G. A randomized, doubleblind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 2000;43:70-5. (Pubitemid 30114095)
100. Wang J, O'Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Med 2009;10:973-5.
101. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009;10:206-11.
102. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445-52.
103. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004;5:231-5. (Pubitemid 38684216)
104. Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Med 2010;11:494-6.
105. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528-30. (Pubitemid 351264124)
106. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2006;21:378-82.
107. Oertel W, Benes H, Garcia-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39. (Pubitemid 351391727)
108. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller J, Oertel W. Patch application of the dopamine agonist rotigotine to patients with moderate to advances stages of restless legs syndrome: A double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-510.
109. Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604.
110. Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83.
111. Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56.
112. Oertel W, Benes H, Garcia-Borreguero D, et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008;9:865-73.
113. Hogl B, Oertel WH, Stiasny-Kolster K, et al. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. BMC Neurol 2010;10:86.
114. Braun M, Cawello W, Boekens H, Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2009;67:209-15.
115. Benes H. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 2006;7:31-5. (Pubitemid 43033542)
116. Benes H, Deissler A, Rodenbeck A, Engfer A, Kohnen R. Lisuride treatment of restless legs syndrome: First studies with monotherapy in de novo patients and in combination with levodopa in advanced disease. J Neural Transm 2006;113:87-92. (Pubitemid 41828959)
117. Evidente VG. Amantadine is beneficial in restless legs syndrome. Mov Disord 2000;16:579-81.
118. Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Scie 1986;13:245-7. (Pubitemid 16042367)
119. Montagna P, Sassoli de Bianchi L, Zucconi M, Cirignotta F, Lugaresi E. Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 1984;69:428-30. (Pubitemid 14080986)
120. Schenck CH, Mahowald MW. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. Am J Med 1996;100:333-7. (Pubitemid 26111631)
121. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) Acute placebocontrolled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001;11:153-61. (Pubitemid 32335558)
122. Shinno H, Oka Y, Otsuki M, et al. Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:522-6.
123. Eisensehr I, Ehrenberg B, Solti S, Noachtar S. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid: A randomized, placebo-controlled, double-blind, cross-over study. J Neurol 2004;251:579-83. (Pubitemid 38680301)
124. Cuellar N, Ratcliffe S. Does Valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med 2009;15:22-8.
125. Baughman K, Bourguet C, Ober S. Gender differences in the association between antidepressant use and restless legs syndrome. Mov Disord 2009;24:1054-9.
126. Kim SW, Shin IS, Kim JM, Park KH, Youn T, Yoon JS. Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Hum Psychopharmacol 2008;23:615-20.
127. Rottach KG, Schaner BM, Kirch MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2008;43:70-5.
128. Leutgeb U, Martus P. Regular intake of non-opioid analgesics is associated with an increased risk of restless legs syndrome in patients maintained on antidepressants. Eur J Med Res 2002;7:368-78.
129. Brown LK, Dedrick DL, Doggett JW, Guido PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 2005;6:443-50. (Pubitemid 41245367)
130. Hornyak M, Grossmann C, Kohnen R, et al. Cognitive behavioural group therapy to improve patients' strategies for coping with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 2008;79:823-5. (Pubitemid 351914733)
131. Lettieri C, Eliasson A. Pneumatic compression devices are an effective therapy for restless legs syndrome. Chest 2009;135:74-80.
132. Eliasson A, Lettieri C. Sequential compression devices for treatment of restless legs syndrome. Medicine 2007;86:317-23. (Pubitemid 351326054)
133. Aukerman M, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: A randomized controlled trial. J Am Board Fam Med 2006;19:487-93. (Pubitemid 44577207)
134. Thorp M, Morris C, Bagby S. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-8. (Pubitemid 32611766)
135. Micozkadioglu H, Ozdemir F, Kut A, Sezer S, Saatci U, Haberal M. Gabapentin versus levodopa for the treatment of restless legs syndrome in hemodialysis patients: An open-label study. Ren Fail 2004;26:393-7. (Pubitemid 39167616)
136. Sloand J, Shelly M, Feigin A, Bernstein P, Monk R. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663-70. (Pubitemid 38401881)
137. Pellecchia M, Vitale C, Sabatini M, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis. Clin Neuropharmacol 2004;27:178-81.
138. Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004;62:831-2. (Pubitemid 38298974)
139. Sakkas G, Hadjigeorigiou G, Karatzaferi C, et al. Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis - A pilot study. ASAIO Journal 2008;54:185-90. (Pubitemid 351450764)
140. Giannaki C, Sakkas GK, Hadjigeorgiou G, et al. Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome. ASAIO Journal 2010;56:538-42.
141. Kerr PG, van Bakel C, Dawborn JK. Assessment of the symptomtic benefit of cool dialysate. Nephron 1989;1989:166-9.
142. Yasuda T, Nishimura A, Katsuki Y, Tsuji Y. Restless legs syndrome treated successfully by kidney transplantation - A case report. Clin Transplants 1986:138.
143. Stautner A, Stiasny K, Collado Seidel V, Bucher SF, Oertel WH, Trenkwalder C. Comparison of idiopathic and uremic restless legs syndrome: results of a database of 134 patients (abstract). Mov Disord 1996;11(Suppl):98.
144. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-DOPA therapy of uremic and idiopathic restless legs syndrome: a double-blind crossover trial. Sleep 1995;18:681-8.
145. Sandyk R, Bernick C, Lee SM, Stern LZ, Iacono RP, Bamford CR. Ldopa in uremic patients with the restless legs syndrome. Int J Neurosci 1987;35:233-5.
146. Walker SL, Fine A, Kryger MH. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-18. (Pubitemid 26138226)
147. Read D, Feest T, Nassim M. Clonazepam: effective treatment for restless legs syndrome in uraemia. Br Med J 1981;283:885-6. (Pubitemid 11000248)
148. Bennett WM, Aronoff GR, eds. Drug prescribing in renal failure. Philadelphia: American College of Physicians, 1994.
149. Sommer M, Bachmann C, Liebetanz K, Schindehutte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007;115:347-50. (Pubitemid 46699434)
150. Hayes CA, Kingsley JR, Hamby KR, Carlow J. The effect of endovenous laser ablation on restless legs syndrome. Phlebology 2008;23:112-7.
151. Kanter AH. The effect of sclerotherapy on restless legs syndrome. Dermatol Surg 1995;21:328-32.
152. Kunz D, Bes F. Exogenous melatonin in Periodic Limb Movement Disorder: An open clinical trial and a hypothesis. Sleep 2001;24:183-7. (Pubitemid 32204194)
153. Ehrenberg B, Eisensehr I, Corbett K, Crowley P, Walters A. Valproate for sleep consolidation in Periodic Limb Movement Disorder. J Clin Psychopharmacol 2000;20:574-8.
154. Grewal M, Hawa R, Shapiro C. Treatment of periodic limb movements in sleep with selegiline HCl. Mov Disord 2002;17:398-401. (Pubitemid 36041313)
155. Godau J, Spinnler N, Wevers AK, Trenkwalder C, Berg D. Poor effect of